Vasculitis & polymyalgia rheumatica
Risks and treatment related aspects of COVID-19 infection in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Authors' conclusion
Our findings highlight risks and suggest that more attention should be given to optimal AAV treatment in a pandemic situation.
Study context
- Population
- Well-characterized AAV cohorts in Stockholm and Uppsala, Sweden, March 2020 to May 2021
- Participants
- 310 participants
- Exposure
- AAV patients with COVID-19 vs without COVID-19
- COVID-19n = 29
- Outcome
- Risk factors and outcomes of COVID-19 (severe COVID-19: need for non-invasive ventilation, ICU care, and/or death)
Methodological detailsmulticentre (Stockholm and Uppsala, Sweden), medical-record review
- Multicentre (Stockholm and Uppsala, Sweden)
- Medical-record review
Main finding
As reported in the abstract
COVID-19 and severe COVID-19
- Diagnosed with COVID-19
- 29 (9%)
- Severe COVID-19
- 9/29 (31%)
- Deaths attributed to COVID-19
- 4
- Risk factor for severe COVID-19: impaired kidney function
- p = 0.01
- Risk factor for severe COVID-19: more intense immunosuppressive therapy
- p = 0.02
- Trend for age
- p = 0.07
Observational data: associations, not effects.
Further findings
On prednisolone
- On prednisolone — Significantly higher prednisolone doses in COVID-19 patients
- p < 0.01
Ongoing induction therapy
- More prevalent in the COVID-19 group
- P < 0.01
Original publication
Risks and treatment related aspects of COVID-19 infection in patients with ANCA-associated vasculitis. Scand J Rheumatol. Published 20 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →